<p>/PRNewswire/ -- Schall 律師事務所是一家全國性的股東權益訴訟事務所，宣佈正在調查 Oculis Holding AG（&#34;Oculis&#34;或&#34;公司&#34;）（NASDAQ: OCS）投資者的索賠，因其違反證券法。</p>
<p>調查的重點是公司是否發佈了虛假和/或誤導性聲明，和/或未能披露對投資者相關的信息。Oculis 聲稱其第三階段 DIAMOND 試驗正在&#34;按計劃推進&#34;，但隨後在 2026 年 5 月 29 日宣佈，兩個 DIAMOND 試驗未能達到其主要終點。公司補充説，基於這些結果，它將不再尋求對其藥物候選者進行 FDA 申請。</p>
<p>如果您是遭受損失的股東，請點擊此處參與。</p>
<p>我們還鼓勵您聯繫 Schall 律師事務所的 Brian Schall，地址：2049 Century Park East, Suite 2460, Los Angeles, CA 90067，電話：310-301-3335，免費討論您的權利。您也可以通過事務所的網站 www.schallfirm.com 或電子郵件 [email protected] 與我們聯繫。</p>
<p>Schall 律師事務所代表全球投資者，專注於證券集體訴訟和股東權益訴訟。</p>
<p>在某些司法管轄區，根據適用法律和倫理規則，本新聞稿可能被視為律師廣告。</p>
<p><strong>聯繫方式：</strong></p>
<p>Schall 律師事務所</p>
<p>Brian Schall, Esq.</p>
<p>310-301-3335</p>
<p>[email protected]</p>
<p>www.schallfirm.com</p>
<p>來源：Schall 律師事務所</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNjA4Jk5ld3NJdGVtSWQ9TEE3NzgyNiZUcmFuc21pc3Npb25fSWQ9MjAyNjA2MDgxMjQzUFJfTkVXU19VU1BSX19fX19MQTc3ODI2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNjA4Jk5ld3NJdGVtSWQ9TEE3NzgyNiZUcmFuc21pc3Npb25fSWQ9MjAyNjA2MDgxMjQzUFJfTkVXU19VU1BSX19fX19MQTc3ODI2"/></p>

<p>Schall 律師事務所正在調查 Oculis Holding AG（納斯達克代碼：OCS）是否存在潛在的證券法違規行為。調查的重點是該公司是否通過聲稱其第三階段 DIAMOND 試驗按計劃推進而發佈了誤導性聲明，然而在 2026 年 5 月 29 日卻宣佈試驗失敗並停止 FDA 申請計劃。遭受損失的投資者被鼓勵聯繫該事務所以討論他們的權利</p>

<p>, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Oculis Holding AG (&#34;Oculis&#34; or &#34;the Company&#34;) (NASDAQ: OCS) for violations of the securities laws.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Schall 律師事務所是一家全國性的股東權益訴訟事務所，宣佈正在調查 Oculis Holding AG（&#34;Oculis&#34;或&#34;公司&#34;）（NASDAQ: OCS）投資者的索賠，因其違反證券法。</p>
</div><p>The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Oculis claimed that its Phase 3 DIAMOND trials were &#34;advancing as planned,&#34; but then announced on May 29, 2026, that both DIAMOND trials failed to meet their primary endpoints. The Company added that based on these results, it would not pursue an FDA filing for its drug candidate.</p>
<div class="lb-trans"><p>調查的重點是公司是否發佈了虛假和/或誤導性聲明，和/或未能披露對投資者相關的信息。Oculis 聲稱其第三階段 DIAMOND 試驗正在&#34;按計劃推進&#34;，但隨後在 2026 年 5 月 29 日宣佈，兩個 DIAMOND 試驗未能達到其主要終點。公司補充説，基於這些結果，它將不再尋求對其藥物候選者進行 FDA 申請。</p>
</div><p>If you are a shareholder who suffered a loss, click here to participate.</p>
<div class="lb-trans"><p>如果您是遭受損失的股東，請點擊此處參與。</p>
</div><p>We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].</p>
<div class="lb-trans"><p>我們還鼓勵您聯繫 Schall 律師事務所的 Brian Schall，地址：2049 Century Park East, Suite 2460, Los Angeles, CA 90067，電話：310-301-3335，免費討論您的權利。您也可以通過事務所的網站 www.schallfirm.com 或電子郵件 [email protected] 與我們聯繫。</p>
</div><p>The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.</p>
<div class="lb-trans"><p>Schall 律師事務所代表全球投資者，專注於證券集體訴訟和股東權益訴訟。</p>
</div><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.</p>
<div class="lb-trans"><p>在某些司法管轄區，根據適用法律和倫理規則，本新聞稿可能被視為律師廣告。</p>
</div><p><strong>CONTACT:</strong></p>
<div class="lb-trans"><p><strong>聯繫方式：</strong></p>
</div><p>The Schall Law Firm</p>
<div class="lb-trans"><p>Schall 律師事務所</p>
</div><p>Brian Schall, Esq.</p>
<div class="lb-trans"><p>Brian Schall, Esq.</p>
</div><p>310-301-3335</p>
<div class="lb-trans"><p>310-301-3335</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>www.schallfirm.com</p>
<div class="lb-trans"><p>www.schallfirm.com</p>
</div><p>SOURCE The Schall Law Firm</p>
<div class="lb-trans"><p>來源：Schall 律師事務所</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNjA4Jk5ld3NJdGVtSWQ9TEE3NzgyNiZUcmFuc21pc3Npb25fSWQ9MjAyNjA2MDgxMjQzUFJfTkVXU19VU1BSX19fX19MQTc3ODI2" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LA77826&amp;Transmission_Id=202606081243PR_NEWS_USPR_____LA77826&amp;DateId=20260608"/></p>

ETOCS 的投資者有機會與 Schall 律師事務所合作，參與對 Oculis Holding AG 的欺詐調查